Core Points - The company Zhejiang Crystal Optoelectronics Technology Co., Ltd. (stock code: 002273) held its seventh board meeting on October 27, 2025, where it approved the Q3 2025 report and a proposal for foreign exchange derivative hedging transactions [1][2] - The Q3 2025 report was unanimously approved with 12 votes in favor and no votes against or abstaining [2] - The board approved a foreign exchange hedging business proposal to mitigate foreign exchange market volatility risks, allowing transactions up to RMB 1 billion within one year [3] Summary by Sections Board Meeting - The board meeting was conducted via telecommunication, with all 12 directors present and all executives in attendance, complying with legal and regulatory requirements [1] Q3 2025 Report - The Q3 2025 report was pre-reviewed by the board's audit committee and disclosed through various media outlets [2] Foreign Exchange Hedging - The board authorized management to conduct foreign exchange derivative hedging transactions up to RMB 1 billion, aimed at stabilizing foreign exchange costs and reducing the impact of exchange rate fluctuations on operational performance [3]

Core Viewpoint - The company has approved the temporary use of idle raised funds to supplement working capital, not exceeding RMB 100 million, ensuring it does not affect the progress of investment projects [9][12][13] Financial Data - The third quarter financial report has not been audited [3][8] - The company reported a net fundraising amount of RMB 869.26 million after deducting issuance costs [9] - The company has previously used idle funds of RMB 130 million and has fully returned it to the special account [11][12] Shareholder Information - The company disclosed a plan for the controlling shareholder to reduce shares, with a maximum of 3,724,392 shares, representing 1.54% of the total share capital [5] - As of October 17, 2025, the controlling shareholder has completed the reduction, totaling 2,847,859 shares, or 1.18% of the total share capital [5] Board Meeting - The third board meeting approved the third quarter report, affirming its accuracy and completeness [20][21] - The board also approved the use of idle funds for working capital, with unanimous support from all attending members [24][25] Risk Management - The company plans to engage in foreign exchange hedging to mitigate risks associated with currency fluctuations, with a limit of USD 8 million or equivalent [38][41] - The hedging activities will be conducted with qualified financial institutions and will not involve speculative trading [39][53]

Core Viewpoint - The company reported a mixed financial performance for the third quarter of 2025, with revenue growth but a decline in net profit compared to the previous year [5][6]. Trading Information Summary - On October 24, 2025, the company's stock closed at 34.83 yuan, down 0.49%, with a turnover rate of 3.96% and a trading volume of 26,400 shares, amounting to a transaction value of 92.31 million yuan [1]. Shareholder Changes - As of the end of the reporting period, the total number of ordinary shareholders was 13,545, with the top two shareholders, Sun Wenqiang and Wang Jixue, holding 26.25% and 14.84% respectively, acting in concert as controlling shareholders [3]. Performance Disclosure Highlights - The company reported a third-quarter revenue of 232 million yuan, a year-on-year increase of 15.89%, and a cumulative revenue of 618 million yuan for the first three quarters, up 21.34% [5]. - The net profit attributable to shareholders for the third quarter was 22.32 million yuan, a decrease of 3.75% year-on-year, while the cumulative net profit for the first three quarters was 58.70 million yuan, reflecting a significant increase of 91.11% [5][10]. - Excluding non-recurring gains and losses, the third-quarter net profit saw a substantial decline of 50.67% year-on-year, while the cumulative growth for the first three quarters was 95.69% [6]. Cash Flow and Financial Ratios - The net cash flow from operating activities was 46.72 million yuan, down 12.70% year-on-year [7]. - The weighted average return on net assets (ROE) was 5.84%, an increase of 2.85 percentage points year-on-year [8]. Company Announcements - The company announced the approval of several resolutions at the third board meeting, including the continuation of foreign exchange hedging activities with a limit not exceeding 400 million yuan, to mitigate exchange rate risks [9][10]. - The company received a compliance opinion from its sponsor, Guotai Junan Securities, confirming that the foreign exchange hedging activities align with operational needs and do not harm the interests of the company and its shareholders [11].

Core Viewpoint - The company aims to enhance its ability to manage foreign exchange risk and mitigate the impact of significant currency fluctuations on its performance by engaging in foreign exchange hedging activities in 2026 [1] Group 1: Foreign Exchange Hedging Strategy - The company and its subsidiaries plan to continue foreign exchange hedging activities with qualified financial institutions in 2026 [1] - The hedging products will include but are not limited to forward foreign exchange contracts, foreign exchange swaps, and foreign exchange options, or combinations of these products [1] - The maximum contract value held on any trading day is expected to not exceed RMB 1 billion or its equivalent in foreign currency [1] Group 2: Authorization and Validity - The authorization for the hedging activities will be valid for a period of 12 months, from January 1, 2026, to December 31, 2026 [1] - The authorized amount can be used in a rolling manner within the specified period [1]

Core Viewpoint - The company has approved a foreign exchange hedging business with a maximum scale of 100 million RMB or equivalent foreign currency over the next twelve months, which can be reused [1] Group 1: Business Overview - The foreign exchange hedging business will be limited to currencies that are the same as the main settlement currencies used in the company's operations [1] - The hedging activities include forward foreign exchange contracts, foreign exchange swaps, currency swaps, foreign exchange options, interest rate swaps, interest rate options, and related combination products [1] Group 2: Regulatory and Counterparty Information - The trading counterparties for the hedging activities will be commercial banks that have been approved by regulatory authorities and possess qualifications for foreign exchange hedging operations [1]

Core Viewpoint - Haichen Co., Ltd. has approved a proposal to conduct foreign exchange hedging business with a limit of up to 500 million RMB or equivalent foreign currency [2] Summary by Relevant Sections Foreign Exchange Hedging Business - The company and its subsidiaries will use their own funds to engage in foreign exchange hedging activities within a limit of 500 million RMB or equivalent foreign currency [2] - The approved limit can be used in a rolling manner throughout the effective period, with the maximum contract value at any point not exceeding the specified limit [2] Financial Implications - The expected margin and premium used in transactions will not exceed 50 million RMB or equivalent foreign currency at any point during the effective period [2]

证券日报网讯 10月20日晚间，宇新股份发布公告称，2025年10月20日，广东宇新能源科技股份有限公 司（以下简称"公司"）召开了第四届董事会第七次会议，审议通过了《关于开展外汇套期保值业务的议 案》，同意公司开展不超过30亿元人民币或其他等值外币额度的外汇套期保值业务，额度在授权期限内 可循环滚动使用，额度使用期限自股东大会会议审议通过之日起12个月内。 （文章来源：证券日报） ...

Core Points - Bid Pharma's stock price decreased by 10.07% this week, closing at 64.77 yuan, with a market capitalization of 5.886 billion yuan [1] - The company plans to conduct foreign exchange hedging to mitigate currency fluctuation risks, with a maximum contract value of 600 million yuan [2][4] - Bid Pharma's initial public offering raised approximately 1.335 billion yuan, with plans to use up to 200 million yuan of idle funds for cash management [3][4] Company Announcements - Bid Pharma intends to engage in foreign exchange hedging, with a limit of 600 million yuan for any single trading day [2][4] - The company has approved the use of up to 200 million yuan of idle raised funds for cash management, focusing on low-risk, liquid financial products [3][4]

Core Viewpoint - Bid Pharma (688073) is actively managing its financial risks through foreign exchange hedging and optimizing the use of idle funds from its IPO, which reflects a strategic approach to enhance financial stability and operational efficiency [1][2][3] Trading Information Summary - As of October 15, 2025, Bid Pharma's stock closed at 68.47 CNY, up by 3.66%, with a turnover rate of 1.71%, a trading volume of 7,414 shares, and a transaction value of 50.07 million CNY [1] - On the same day, the net inflow of main funds was 28.05 thousand CNY, accounting for 0.56% of the total transaction value, while retail investors saw a net inflow of 721.24 thousand CNY, representing 14.4% of the total [1] Company Announcements Summary - Bid Pharma plans to conduct foreign exchange hedging to mitigate currency fluctuation risks due to its import and export operations, with a maximum contract value of 600 million CNY and a margin and premium not exceeding 20 million CNY, funded by its own resources [1] - The company has established a foreign exchange risk management system and has received approval from its board for this hedging activity, which is valid for 12 months [1] - Additionally, Bid Pharma intends to utilize up to 200 million CNY of temporarily idle funds from its IPO for cash management, focusing on safe, liquid, and short-term investment products [2] - This cash management plan has also been approved by the company's board and is expected to enhance the efficiency of fund utilization without affecting the ongoing investment projects [2]

Core Viewpoint - The company reported a mixed financial performance for the third quarter of 2025, with a slight decline in revenue but an increase in net profit year-to-date, alongside a proposed cash dividend distribution to shareholders [6][9]. Financial Performance - For the reporting period, the company's operating revenue was 575,054,107.17 yuan, a year-on-year decrease of 1.30%. Year-to-date revenue reached 1,787,897,027.71 yuan, reflecting an 8.66% increase [6]. - The net profit attributable to shareholders for the reporting period was 73,729,121.81 yuan, down 4.42% year-on-year. However, year-to-date net profit was 230,246,126.87 yuan, up 15.26% [6]. - The basic earnings per share for the reporting period was 0.38 yuan, a decrease of 2.56% year-on-year, while year-to-date earnings per share was 1.16 yuan, an increase of 16.00% [7]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was 320,121,802.52 yuan, a significant increase of 208.98% [7]. - Total assets at the end of the reporting period amounted to 3,223,281,935.28 yuan, representing a growth of 16.37% compared to the end of the previous year [7]. - Shareholders' equity attributable to the company was 2,354,628,238.19 yuan, up 25.28% from the previous year [7]. Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders was 17,310, with Hainan Linke Investment Co., Ltd. holding a controlling stake of 45.69% [3]. - The top ten unrestricted shareholders included Hainan Linke Investment Co., Ltd., which held 98,939,604 shares [5]. Dividend Distribution - The board approved a cash dividend distribution of 3.00 yuan per 10 shares (including tax), totaling 64,224,588.00 yuan, based on the total share capital after deducting repurchased shares [9]. Other Announcements - The board also approved a proposal for the company to engage in foreign exchange hedging activities, with an authorized limit not exceeding 20 million USD [11].